An interventional study of Multisensory room therapy and Standard behavioural therapy in Autism Spectrum Disorder, Parenting Stress and Sensory Processing Disorder, sponsored by SERGIO MONTERO NAVARRO. Not yet recruiting. Open to participants aged 3 Years to 12 Years. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by SERGIO MONTERO NAVARRO · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this clinical trial is to learn whether therapy in a multisensory room improves sensory processing, behavioural and attentional regulation and stress in children aged 3 to 12 years with autism spectrum disorder (support level 2-3), and whether it reduces stress in their main caregivers. The main question it aims to answer is: does sensory processing (Sensory Profile 2) change more after 8 weeks of multisensory room therapy than after 8 weeks of standard behavioural therapy? Researchers will also compare executive function, attention and behaviour, parental stress, and stress-related biomarkers in saliva (cortisol, oxytocin and inflammatory interleukins). They will also record physiological stress signals in caregivers (heart rate, skin conductance, breathing and temperature).
Sixty children will be randomly assigned to one of two groups. Children in the first group will receive two individual 45-minute multisensory room sessions per week for 8 weeks. Children in the second group will receive standard behavioural therapy with psychology and speech therapy, without multisensory stimulation. Caregivers will complete questionnaires and give saliva samples before and after the 8-week programme.
Background. Sensory processing differences are highly prevalent in autism spectrum disorder (ASD) and are associated with anxiety, emotional dysregulation and lower adaptive functioning. Children with ASD show atypical activation of the hypothalamic-pituitary-adrenal axis and elevated pro-inflammatory cytokines. Parents of children with ASD report high parenting stress. Multisensory environments (Snoezelen®) are widely used to support self-regulation, but controlled trials with objective outcomes are scarce.
Design. Randomised, controlled, parallel-group trial with pre-post assessment. Families with a child aged 3-12 years with ASD (support level 2-3) attending the Centre de Teràpia Interfamiliar (Elche, Spain) are randomised 1:1. Randomisation is stratified by age, sex and the primary outcome, in blocks of two, and the sequence is concealed. Outcome assessors are blinded to group allocation; therapists cannot be blinded.
Interventions. Multisensory group: 16 individual 45-minute sessions (2 per week for 8 weeks) in a multisensory room, delivered by occupational therapists trained in multisensory stimulation in ASD. Each session follows a semi-structured protocol: welcome and adaptation (5 min); guided sensory regulation with graded visual, auditory, tactile, vestibular and proprioceptive stimuli (15-20 min); active participation and control of the environment (10-15 min); and closure with return to calm (5 min). Control group: 45-minute sessions of standard behavioural therapy with psychology and speech therapy, under standard lighting, without therapeutic multisensory stimuli and with the same therapist presence.
Assessments. Baseline (T0): child saliva biomarkers; caregiver-reported Sensory Profile 2, BRIEF-P/BRIEF-2, Conners scales and PSI-SF; caregiver saliva and hair biomarkers; and caregiver physiological recording (BIOPAC MP36R). During the intervention (T1): child saliva before and after each session, and a structured observational self-regulation record after each session. After 8 weeks (T2): caregiver-reported scales, caregiver biomarkers and physiological recording. Salivary cortisol, oxytocin, IL-6, IL-1β, IL-17A and TNF-α are analysed by ELISA at Universidad CEU Cardenal Herrera.
Setting and data. The study is conducted at the Centre de Teràpia Interfamiliar (Elche, Spain) in collaboration with the Neurobiology research group of Universidad CEU Cardenal Herrera. Data are pseudonymised and handled in accordance with the GDPR and Spanish Organic Law 3/2018.
1,733 studies on the registry are indexed under Autism Spectrum Disorder; 504 are open to participants now.
This study's planned enrollment of 120 is above the median of 52 across 1,373 interventional studies indexed under Autism Spectrum Disorder.
Browse Autism Spectrum Disorder studies →SERGIO MONTERO NAVARRO is the lead sponsor of 4 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria (children):
Exclusion Criteria (children):
Inclusion Criteria (caregivers):
Exclusion Criteria (caregivers):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Children with ASD receive 8 individual 45-minute sessions (1 per week for 8 weeks) in a multisensory room. Their caregivers complete assessments and provide biological samples.
Behavioral: Multisensory room therapy
Children with ASD receive 45-minute sessions of standard behavioural therapy (psychology and speech therapy) without multisensory stimulation, over the same 8-week period. Their caregivers complete the same assessments.
Behavioral: Standard behavioural therapy
Semi-structured individual session in a multisensory (Snoezelen®) room delivered by occupational therapists trained in multisensory stimulation in ASD: (1) welcome and adaptation, 5 min, with dim light and no loud sounds; (2) guided sensory regulation, 15-20 min, with graded visual, auditory, tactile, vestibular and proprioceptive stimuli adjusted to the child's profile; (3) active participation and control of the environment, 10-15 min, in which the child chooses or modulates stimuli; (4) closure and return to calm, 5 min. Two sessions per week for 8 weeks.
Also known as: Snoezelen; Multisensory environment (MSE)
45-minute session with psychology and speech therapy addressing children with ASD support level 2-3, under standard lighting, without therapeutic multisensory stimuli, and with the same therapist presence as the experimental arm.
Change in sensory hyper-reactivity (Sensory Profile 2, Sensitivity quadrant)
Sensory Profile 2 - Child form, completed by the main caregiver. Raw score of the Sensitivity quadrant (19 items, each rated from 1 = almost never to 5 = almost always; range 19-95). Higher scores indicate more frequent sensory hyper-reactivity (worse outcome).
Time frame: Baseline and week 8
Change in executive function (Behavior Rating Inventory of Executive Function, BRIEF-P / BRIEF-2)
Behavior Rating Inventory of Executive Function - Preschool Version (BRIEF-P, ages 3-5) or BRIEF-2 parent form (ages 5-12), completed by the main caregiver. Global Executive Composite raw score (63 items rated 1-3; range 63-189). Higher scores indicate greater executive dysfunction (worse outcome).
Time frame: Baseline and week 8
Change in emotional and behavioural problems (SENA, Global Problems Index)
Child and Adolescent Assessment System (SENA), family-report form for ages 3-6 or 6-12, completed by the main caregiver. Global Problems Index, T-score (normative mean 50, SD 10; range of risk 65-69; significative range of risk: \>70). Higher scores indicate more emotional and behavioural problems (worse outcome).
Time frame: Baseline and week 8
Parenting stress (PSI-SF)
PSI-SF is a 36-item, self-report measure of parenting stress. It includes three subscales: Parental Distress (PD; e.g, "I feel trapped by my responsibilities as a parent", "I feel lonely and without friends"), Parent-Child Dysfunctional Interaction (PCDI; e.g, "Sometimes I feel my child doesn't like me and doesn't want to be close to me", "When I do things for my child I get the feeling that my efforts are not appreciated" ), and Difficult Child (DC; e.g, "My child makes more demands on me than most children", "My child gets upset easily over the smallest thing"). Each subscale consists of 12 items rated from 1 (strongly disagree) to 5 (strongly agree), with subscales scores ranging from 12 to 60. A Total score is calculated by summing the three subscales scores, ranging from 36 to 180. Scores of 90 or above may indicate a clinical level of stress.
Time frame: Baseline and week 8
Child salivary cortisol (ng/mL)
ELISA Kits ' Cortisol ELISA Kits Human Cortisol Competitive ELISA Kit ,Invitrogen. Quantification of cortisol: RT-2100C microplate reader, which is a general-purpose microprocessor-controlled photometric system designed to read and calculate biomarker assay results (optic ivymen system)
Time frame: Baseline and before/after each session, weeks 1-8
Child salivary oxytocin (pg/mL)
ELISA Kits ' Cortisol ELISA Kits Human Cortisol Competitive ELISA Kit ,Invitrogen. Quantification of oxytocin: RT-2100C microplate reader, which is a general-purpose microprocessor-controlled photometric system designed to read and calculate biomarker assay results (optic ivymen system)
Time frame: Baseline and before/after each session, weeks 1-8
Child salivary pro-inflammatory cytokines
Salivary IL-6, IL-1β, IL-17A and TNF-α (pg/mL, ELISA).
Time frame: Baseline and before/after each session, weeks 1-8
Caregiver stress biomarkers - Salivary cortisol (ng/mL)
Time frame: Baseline and week 8
Caregiver stress biomarkers - oxytocin (pg/mL)
Time frame: Baseline and week 8
Caregiver stress biomarkers - IL-6, IL-1β, IL-17A and TNF-α (pg/mL) (ELISA)
Time frame: Baseline and week 8
Caregiver stress biomarkers - hair cortisol (pg/mg)
Time frame: Baseline and week 8
In-session self-regulation (observational record)
Therapist-rated 8-item record (0-3 per item; total 0-24). Higher scores indicate greater self-regulation difficulty.
Time frame: After each session, weeks 1-8
Heart rate and heart rate variability (LF, HF, LF/HF ratio). BIOPAC MP36R device
During a recording of about 30 minutes
Time frame: Baseline and week 8
Galvanic response by means of Skin conductance (SC). micro-siemens or micro-omhios. BIOPAC MP36R device
During a recording of about 30 minutes
Time frame: Baseline and week 8
Breathing rate (breaths per minute). BIOPAC MP36R device
During a recording of about 30 minutes
Time frame: Baseline and week 8
Skin temperature (ºC). BIOPAC MP36R device
During a recording of about 30 minutes
Time frame: Baseline and week 8
Adverse events
Number of children with behavioural crises, sensory overload requiring session interruption, or other adverse events, by group.
Time frame: Weeks 1-8
No study locations are listed for this record.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided — Coded data may be shared only for purposes consistent with the study and under confidentiality guarantees; no international transfers are planned.
Start is estimated for Jan 2027; primary completion for Mar 2027, 2 months later.
Of 805 non-industry interventional studies with no phase under Autism Spectrum Disorder, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 48. This study's planned 2 months is below that.
Counting every sponsor, half of 828 studies reached it within 25 months; a quarter within 12 and three quarters within 47.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
SERGIO MONTERO NAVARRO